CORRECTION article

Front. Oncol., 13 December 2023

Sec. Cancer Immunity and Immunotherapy

Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1338060

Corrigendum: Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

  • Department of Oncology, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China

Text Correction

In the published article, there was an error in section 3.1.5 Pembrolizumab in combination with lenvatinib regimen

This sentence previously stated: “A multicenter, double-blind, randomized phase III LEAP-012 study showed no significant improvement in the efficacy of systemic combination TACE in combination with lenvatinib + pembrolizumab compared to TACE alone in patients with intermediate-stage HCC.”

The corrected sentence appears below:

“A multicenter, double-blind, randomized phase III LEAP-012 study is underway, which evaluates the efficacy of systemic combination TACE in combination with lenvatinib + pembrolizumab compared to TACE alone in patients with intermediate-stage HCC.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

targeted therapy, immunotherapy, research progress, hepatocellular carcinoma, combination therapy

Citation

Xie S, Wang M, Zeng C, Ou Y, Zhao L, Wang D, Chen L, Kong F and Yi D (2023) Corrigendum: Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma. Front. Oncol. 13:1338060. doi: 10.3389/fonc.2023.1338060

Received

14 November 2023

Accepted

23 November 2023

Published

13 December 2023

Volume

13 - 2023

Edited and reviewed by

Zong Sheng Guo, University at Buffalo, United States

Updates

Copyright

*Correspondence: Liwei Chen,

†These authors have contributed equally to this work and share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics